Abstracts
P43
Cell and gene therapy of metabolic diseases
V Nieto-Romero
Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) and Instituto de Investigación Sanitaria Fundación Jiménez. (IIS-FJD, UAM), 28040 Madrid, Spain
Restoration of glyoxylate detoxification capacity of induced-hepatocytes after gene editing of the AGXT gene: A potential treatment for Primary Hyperoxaluria type I
P44
Cell and gene therapy of metabolic diseases
M I Garín
Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Centre for Biomedical Network Research on Rare Diseases (CIBER-ER) and Advanced Therapy Unit, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM).
Galectin-1 is required for the immune modulatory function of FOXP3+CD4+ Treg cells in the intestine
P45
Cell and gene therapy of metabolic diseases
M I Garín
Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Centre for Biomedical Network Research on Rare Diseases (CIBER-ER) and Advanced Therapy Unit, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM).
Role of galectin-1 in regulatory T cell-based therapy in chronic colitis
P47
Cell and gene therapy of metabolic diseases
L Neire
Vivet Therapeutics, S.L., Pamplona, Spain.
rAAV-mediated gene therapy in combination with short-term nitrogen-scavenger treatment corrects biochemical and behavioral abnormalities and increases lifespan in infant Citrullinemia Type 1 (CTLN-1) mice
P48
Cell and gene therapy of metabolic diseases
M Hommel
Division of Gene Therapy and Regulation of Gene Expression, CIMA, University of Navarra, Pamplona, Spain; Institute for Sanitary Research (IdiSNA), Pamplona, Spain
Optimizing the IdeS treatment regimen for enhanced adeno-associated virus transduction in the presence of neutralizing antibodies

